Life-2023-02 Esophagogastric Variceal Bleeding

Zhejiang University

Status: Enrolling

Conditions: Acute Esophageal Variceal Hemorrhage

Treatments: Drug: Growth Inhibitor

Study type: Interventional

Funder types: Other

Identifiers

NCT06011980

2023-0407

Details and patient eligibility

About

Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding

Full description

Participants with acute esophagogastric variceal bleeding in 5 days and under stable status will be included in this study. All the patients will take CTP test to confirm the blood flow status of the portal vein before endoscopic treatment. After that they will be randomly divided into two groups: A. accept growth inhibitors after the endoscopic treatment for 5 days; B. no growth inhibitor will be applied after the treatment.

Enrollment: 33 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• acute esophagogastric bleeding with hepatic cirhosis;
• stable status (no active bleeding)

Exclusion criteria

• endoscopic test limitation;
• previous acute esophagogastric bleeding treatment history;
• ICU;
• pregnant;
• Immunity disabled;

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

33 participants in 2 patient groups

Group A

Experimental group

Description:

Participants in this group will take growth inhibitors for 5 days after endoscopic treatment.

Treatment:

Drug: Growth Inhibitor

Group B

No Intervention group

Description:

Participants in this group will not take growth inhibitor treatment after endoscopic treatment.